FDA Expands Xolair to Younger Kids With Allergic AsthmaFDA Expands Xolair to Younger Kids With Allergic Asthma

Omalizumab is now indicated in children as young as age 6 years with uncontrolled moderate to severe persistent allergic asthma. FDA Approvals
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Allergy & Clinical Immunology News Alert Source Type: news